NCT06697600Recruiting
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
This is a multicenter randomized controlled trial that assesses the efficacy of a decisional intervention \[University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL)\] compared to an attention control.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1020 (estimated)
- First submitted
- 14 Nov 2024
- Start date
- 11 Jul 2025
- Primary completion date
- 1 Oct 2029
- Lead sponsor
- University of Rochester
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06697600
What you commit to
- Study type: Interventional
- Planned participants: 1020
- From 11 Jul 2025 to the primary completion date, 1 Oct 2029
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Age ≥60 years (from date of consent, confirmed on electronic medical records)
- A new diagnosis of AML
- Diagnosis can be based on the International Consensus Classification or World Health Organization
- Myeloid sarcoma is allowed
- AML with central nervous system involvement is allowed
- Cancer-directed treatment has not started
- Treatment to temporarily decrease white blood cells is acceptable; these may include hydroxyurea, leukapheresis, or cytarabine
- Intrathecal chemotherapy is acceptable
- The patient's oncologist has been or will be enrolled on the study
- English or Spanish-speaking
- Patients without a caregiver will still be eligible to participate in the study Exclusion criteria
- A diagnosis of acute promyelocytic leukemia
- Patients with psychiatric or cognitive conditions which the treating oncologist believes prohibits informed consent or compliance with study procedures
- Prior cancer-directed treatment for AML
- Caregivers
- Selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 18 or older\] with whom you discuss or who can be helpful in healthrelated matters."
- Caregiver may be paid/professional or informal caregiver
- Able to provide informed consent
- English or Spanish-speaking
- Oncologists
- Oncologists caring for patients with AML Exclusion criteria
Criteria the registry did not label
- Patients
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham, Division of Hematology and Oncology Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| University of North Carolina Lineberger Comprehensive Cancer Center Coordinator of this site? Confirm its status | Chapel Hill | United States | Recruiting |
| University of Rochester Medical Center Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.